Choosing between CJC-1295 with DAC or without DAC? This decision significantly impacts your research protocol. While they share the same base structure, the addition of Drug Affinity Complex (DAC) creates fundamentally different pharmacokinetics and dosing requirements.
Important: All compounds discussed in this article are intended strictly for research purposes only and are not for human consumption or clinical use. This content is educational and does not constitute medical advice.
Here’s what you need to know. CJC-1295 with DAC lasts about 6-8 days in the system, allowing weekly dosing. CJC-1295 without DAC (also called Modified GRF 1-29) has a 30-minute half-life requiring multiple daily doses. Let’s explore which suits different research applications.
DAC stands for Drug Affinity Complex. It’s a chemical modification that changes how long the peptide stays active in circulation.
The mechanism is well-characterized in the literature. Research published in Endocrinology demonstrated that DAC enables CJC-1295 to form covalent bioconjugates with serum albumin, producing a 4-fold increase in growth hormone area under the curve compared to native hGRF(1-29) (Jetté et al., 2005). Albumin is an abundant blood protein. When CJC-1295 binds to it, the peptide becomes protected from enzymatic breakdown and kidney clearance.
This simple modification has profound effects. It extends the half-life from minutes to days.
CJC-1295 WITH DAC: The Long-Acting Version
Half-Life: A landmark clinical trial published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 with DAC has an estimated half-life of 5.8 to 8.1 days, with dose-dependent increases in plasma GH concentrations by 2- to 10-fold for 6 days or more (Teichman et al., 2006). This means the peptide remains active for over a week after a single injection.
How It Works: CJC-1295 with DAC provides sustained, steady elevation in growth hormone and IGF-1. It continuously stimulates the pituitary gland to release more growth hormone throughout the day and night. Research confirmed that pulsatile GH secretion persists even during continuous CJC-1295 stimulation, with basal GH levels increasing 7.5-fold and overall IGF-1 levels rising approximately 45% (Ionescu & Frohman, 2006).
Dosing Schedule: The long half-life allows once or twice weekly injections in research protocols. Most study designs use weekly dosing for convenience.
Release Pattern: Creates a constant baseline elevation rather than distinct pulses. Growth hormone levels stay moderately elevated around the clock.
Fewer injections means less injection site rotation concern
Easier adherence for research protocols
Consistent blood levels
Potential Drawbacks:
Less physiological than pulsatile release
Cannot “turn off” quickly if side effects occur
May suppress natural GH pulses with continuous stimulation
Takes longer to clear system if discontinuation needed
CJC-1295 WITHOUT DAC: Modified GRF 1-29
Alternative Names: CJC-1295 without DAC is also known as Modified GRF 1-29 or Mod GRF 1-29. These are the same compound—a tetrasubstituted form of hGRF(1-29) with amino acid substitutions at positions 2, 8, 15, and 27 to resist enzymatic degradation.
Half-Life: Only 30 minutes to 2 hours. The peptide is cleared from the system quickly, which is characteristic of unmodified GHRH analogs without albumin-binding technology.
How It Works: The short half-life means it mimics the body’s natural pulsatile release of GHRH. Each administration creates a distinct pulse of growth hormone, similar to natural physiological patterns. Research on GHRH analogs has shown that short-term treatment augments both basal and pulsatile GH secretion while preserving insulin sensitivity (Stanley et al., 2011).
Dosing Schedule: CJC-1295 without DAC requires more frequent administration—typically 2-3 times daily in research protocols to maintain sustained effect.
Release Pattern: Creates episodic pulses of growth hormone rather than constant elevation. This more closely mimics natural GH patterns.
Note: All peptides discussed here are sold strictly for in vitro research and laboratory use. These products are not intended for human or animal consumption.
Advantages:
More physiological pulsatile release pattern
Better preserved natural GH rhythms
Can be timed strategically in research protocols
Clears system quickly if issues arise
May reduce receptor desensitization
Often combined with GHRP peptides for synergy
Potential Drawbacks:
Requires multiple daily administrations
More demanding protocol adherence
More injection sites to rotate
Higher total injection volume over time
More complex to maintain consistent levels
Comparing Effectiveness
Both versions work, but differently:
Growth Hormone Response: Clinical studies show both increase GH and IGF-1 levels. The landmark Teichman et al. (2006) trial demonstrated that CJC-1295 with DAC produced dose-dependent GH increases of 2- to 10-fold sustained over 6+ days, with IGF-1 elevations of 1.5- to 3-fold persisting for 9-11 days. The without-DAC version creates higher peaks but lower troughs due to its pulsatile pattern.
IGF-1 Production: CJC-1295 with DAC typically produces more sustained IGF-1 elevation. Proteomic analysis has identified specific serum protein profile changes correlating with IGF-1 axis activation following CJC-1295 administration (Sackmann-Sala et al., 2009). The without-DAC version shows more variable IGF-1 levels corresponding to its pulsatile GH release.
Receptor Sensitivity: Some researchers theorize that constant stimulation from the DAC version may lead to receptor downregulation over time. The pulsatile pattern from non-DAC version might better preserve receptor sensitivity. However, concrete evidence for this in humans is limited. Notably, animal studies showed that daily CJC-1295 administration normalized growth in GHRH knockout mice, including body weight, length, and bone development (Alba et al., 2006).
You’re combining with GHRP peptides (Ipamorelin, GHRP-2, GHRP-6)
You prefer the flexibility of timing doses
You don’t mind multiple daily injections
You want quick system clearance if needed
Frequently Asked Questions
Can you combine both versions?
This isn’t typically done since they’re variations of the same compound. You would choose one or the other. However, the without-DAC version is commonly combined with GHRP peptides like Ipamorelin for synergistic effects.
Is one version more expensive than the other?
CJC-1295 with DAC tends to be slightly more expensive per vial due to the additional manufacturing step. However, because you need less frequent dosing, the total cost over time may be similar or even lower than the without-DAC version.
Which version is better for beginners?
Many researchers find the with-DAC version easier to start with due to simpler dosing. Once weekly injections are more forgiving of schedule variations. The without-DAC version requires more commitment to multiple daily doses.
Does the DAC version cause more side effects?
Both versions have similar side effect profiles related to increased growth hormone. However, because the DAC version provides constant stimulation, side effects can’t be timed as strategically. The without-DAC version allows you to avoid dosing if experiencing issues.
Can you switch between versions mid-protocol?
Yes, but account for different half-lives when transitioning. When switching from with-DAC to without-DAC, wait 7-10 days for the long-acting version to clear. When going the other direction, you can start immediately.
Which produces better results in research settings?
Both can support growth hormone research effectively. Some researchers prefer the pulsatile pattern of the without-DAC version for timing-sensitive protocols, while others favor the constant anabolic environment from the DAC version. Individual research outcomes vary.
Is Modified GRF 1-29 exactly the same as CJC-1295 without DAC?
Yes. Modified GRF 1-29 and CJC-1295 without DAC are identical. The different names create confusion, but they’re the same peptide sequence—a tetrasubstituted analog of growth hormone-releasing factor (1-29).
How long should each version be used in research protocols?
Typical protocols run 8-12 weeks followed by a break. Some researchers cycle continuously, while others prefer periodic breaks to maintain sensitivity. The DAC version may benefit more from cycling due to constant stimulation.
Which version is safer long-term?
Neither has extensive long-term safety data from controlled trials. Theoretically, the without-DAC version’s pulsatile pattern more closely mimics natural physiology, which might be preferable for extended research. However, this remains speculative.
Yes, both versions work similarly regardless of sex. Research protocols may adjust dosing, but both types can be used effectively. The main considerations are the same: convenience versus physiological pulsing.
Combination Protocols
How each version fits into combination protocols differs:
CJC-1295 WITH DAC: Often used as a standalone GH secretagogue. The sustained release doesn’t require precise timing with other peptides. Some combine it with weekly GHRP dosing for additional pulses.
CJC-1295 WITHOUT DAC: Commonly combined with GHRP peptides (Ipamorelin, GHRP-2, GHRP-6). Administered together 2-3 times daily, they create strong synergistic GH pulses. This combination is popular for its effectiveness and physiological pattern.
CJC-1295 with DAC and without DAC are both effective growth hormone secretagogues with different practical applications. The DAC version offers convenience with weekly dosing and sustained GH elevation. The without-DAC version provides more physiological pulsatile release but requires multiple daily injections.
Your choice depends on research goals, protocol design, and whether you’re combining with other peptides. Neither is inherently superior—they serve different purposes. Many researchers eventually try both to compare response in their specific experimental context.
For convenience and simplicity, the DAC version wins. For physiological mimicry and combination protocols, the without-DAC version is preferred. Both can produce meaningful results when used consistently within well-designed research frameworks.
Ready to explore growth hormone research? Check out our CJC-1295 and combination products to support your research protocols.
References
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PubMed
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PubMed
Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PubMed
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. PubMed
Disclaimer: All peptides and products mentioned are strictly for research purposes only and are not for human or animal use. This content is for informational purposes only and should not be considered medical advice. Always consult qualified professionals before starting any research protocol.
Curious about how BPC-157 peptide supports tendon-repair, gut recovery, and anti-inflammatory action? Dive in as we explore whether its unique gut healing boost through angiogenesis is always a positive—or if there’s more to the story than meets the eye.
When it comes to the safe reconstitution of sensitive compounds, not all water is created equal. Discover the simple but powerful ingredient that makes this sterile solution a lab essential for keeping your materials pure and stable.
CJC-1295 with DAC or Without DAC?
Choosing between CJC-1295 with DAC or without DAC? This decision significantly impacts your research protocol. While they share the same base structure, the addition of Drug Affinity Complex (DAC) creates fundamentally different pharmacokinetics and dosing requirements.
Important: All compounds discussed in this article are intended strictly for research purposes only and are not for human consumption or clinical use. This content is educational and does not constitute medical advice.
Here’s what you need to know. CJC-1295 with DAC lasts about 6-8 days in the system, allowing weekly dosing. CJC-1295 without DAC (also called Modified GRF 1-29) has a 30-minute half-life requiring multiple daily doses. Let’s explore which suits different research applications.
$55.00 – $95.00Price range: $55.00 through $95.00
$100.00 – $160.00Price range: $100.00 through $160.00
$35.00 – $50.00Price range: $35.00 through $50.00
$35.00 – $50.00Price range: $35.00 through $50.00
Understanding DAC: The Key Difference
DAC stands for Drug Affinity Complex. It’s a chemical modification that changes how long the peptide stays active in circulation.
The mechanism is well-characterized in the literature. Research published in Endocrinology demonstrated that DAC enables CJC-1295 to form covalent bioconjugates with serum albumin, producing a 4-fold increase in growth hormone area under the curve compared to native hGRF(1-29) (Jetté et al., 2005). Albumin is an abundant blood protein. When CJC-1295 binds to it, the peptide becomes protected from enzymatic breakdown and kidney clearance.
This simple modification has profound effects. It extends the half-life from minutes to days.
CJC-1295 WITH DAC: The Long-Acting Version
Half-Life: A landmark clinical trial published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 with DAC has an estimated half-life of 5.8 to 8.1 days, with dose-dependent increases in plasma GH concentrations by 2- to 10-fold for 6 days or more (Teichman et al., 2006). This means the peptide remains active for over a week after a single injection.
How It Works: CJC-1295 with DAC provides sustained, steady elevation in growth hormone and IGF-1. It continuously stimulates the pituitary gland to release more growth hormone throughout the day and night. Research confirmed that pulsatile GH secretion persists even during continuous CJC-1295 stimulation, with basal GH levels increasing 7.5-fold and overall IGF-1 levels rising approximately 45% (Ionescu & Frohman, 2006).
Dosing Schedule: The long half-life allows once or twice weekly injections in research protocols. Most study designs use weekly dosing for convenience.
Release Pattern: Creates a constant baseline elevation rather than distinct pulses. Growth hormone levels stay moderately elevated around the clock.
Advantages:
Potential Drawbacks:
CJC-1295 WITHOUT DAC: Modified GRF 1-29
Alternative Names: CJC-1295 without DAC is also known as Modified GRF 1-29 or Mod GRF 1-29. These are the same compound—a tetrasubstituted form of hGRF(1-29) with amino acid substitutions at positions 2, 8, 15, and 27 to resist enzymatic degradation.
Half-Life: Only 30 minutes to 2 hours. The peptide is cleared from the system quickly, which is characteristic of unmodified GHRH analogs without albumin-binding technology.
How It Works: The short half-life means it mimics the body’s natural pulsatile release of GHRH. Each administration creates a distinct pulse of growth hormone, similar to natural physiological patterns. Research on GHRH analogs has shown that short-term treatment augments both basal and pulsatile GH secretion while preserving insulin sensitivity (Stanley et al., 2011).
Dosing Schedule: CJC-1295 without DAC requires more frequent administration—typically 2-3 times daily in research protocols to maintain sustained effect.
Release Pattern: Creates episodic pulses of growth hormone rather than constant elevation. This more closely mimics natural GH patterns.
Note: All peptides discussed here are sold strictly for in vitro research and laboratory use. These products are not intended for human or animal consumption.
Advantages:
Potential Drawbacks:
Comparing Effectiveness
Both versions work, but differently:
Growth Hormone Response: Clinical studies show both increase GH and IGF-1 levels. The landmark Teichman et al. (2006) trial demonstrated that CJC-1295 with DAC produced dose-dependent GH increases of 2- to 10-fold sustained over 6+ days, with IGF-1 elevations of 1.5- to 3-fold persisting for 9-11 days. The without-DAC version creates higher peaks but lower troughs due to its pulsatile pattern.
IGF-1 Production: CJC-1295 with DAC typically produces more sustained IGF-1 elevation. Proteomic analysis has identified specific serum protein profile changes correlating with IGF-1 axis activation following CJC-1295 administration (Sackmann-Sala et al., 2009). The without-DAC version shows more variable IGF-1 levels corresponding to its pulsatile GH release.
Receptor Sensitivity: Some researchers theorize that constant stimulation from the DAC version may lead to receptor downregulation over time. The pulsatile pattern from non-DAC version might better preserve receptor sensitivity. However, concrete evidence for this in humans is limited. Notably, animal studies showed that daily CJC-1295 administration normalized growth in GHRH knockout mice, including body weight, length, and bone development (Alba et al., 2006).
$55.00 – $95.00Price range: $55.00 through $95.00
$100.00 – $160.00Price range: $100.00 through $160.00
$35.00 – $50.00Price range: $35.00 through $50.00
$35.00 – $50.00Price range: $35.00 through $50.00
Which Should You Choose?
Your choice depends on research goals and practical considerations:
Choose CJC-1295 WITH DAC if:
Choose CJC-1295 WITHOUT DAC (Mod GRF 1-29) if:
Frequently Asked Questions
Can you combine both versions?
This isn’t typically done since they’re variations of the same compound. You would choose one or the other. However, the without-DAC version is commonly combined with GHRP peptides like Ipamorelin for synergistic effects.
Is one version more expensive than the other?
CJC-1295 with DAC tends to be slightly more expensive per vial due to the additional manufacturing step. However, because you need less frequent dosing, the total cost over time may be similar or even lower than the without-DAC version.
Which version is better for beginners?
Many researchers find the with-DAC version easier to start with due to simpler dosing. Once weekly injections are more forgiving of schedule variations. The without-DAC version requires more commitment to multiple daily doses.
Does the DAC version cause more side effects?
Both versions have similar side effect profiles related to increased growth hormone. However, because the DAC version provides constant stimulation, side effects can’t be timed as strategically. The without-DAC version allows you to avoid dosing if experiencing issues.
Can you switch between versions mid-protocol?
Yes, but account for different half-lives when transitioning. When switching from with-DAC to without-DAC, wait 7-10 days for the long-acting version to clear. When going the other direction, you can start immediately.
Which produces better results in research settings?
Both can support growth hormone research effectively. Some researchers prefer the pulsatile pattern of the without-DAC version for timing-sensitive protocols, while others favor the constant anabolic environment from the DAC version. Individual research outcomes vary.
Is Modified GRF 1-29 exactly the same as CJC-1295 without DAC?
Yes. Modified GRF 1-29 and CJC-1295 without DAC are identical. The different names create confusion, but they’re the same peptide sequence—a tetrasubstituted analog of growth hormone-releasing factor (1-29).
How long should each version be used in research protocols?
Typical protocols run 8-12 weeks followed by a break. Some researchers cycle continuously, while others prefer periodic breaks to maintain sensitivity. The DAC version may benefit more from cycling due to constant stimulation.
Which version is safer long-term?
Neither has extensive long-term safety data from controlled trials. Theoretically, the without-DAC version’s pulsatile pattern more closely mimics natural physiology, which might be preferable for extended research. However, this remains speculative.
Can women use both versions equally?
Yes, both versions work similarly regardless of sex. Research protocols may adjust dosing, but both types can be used effectively. The main considerations are the same: convenience versus physiological pulsing.
Combination Protocols
How each version fits into combination protocols differs:
CJC-1295 WITH DAC: Often used as a standalone GH secretagogue. The sustained release doesn’t require precise timing with other peptides. Some combine it with weekly GHRP dosing for additional pulses.
CJC-1295 WITHOUT DAC: Commonly combined with GHRP peptides (Ipamorelin, GHRP-2, GHRP-6). Administered together 2-3 times daily, they create strong synergistic GH pulses. This combination is popular for its effectiveness and physiological pattern.
$55.00 – $95.00Price range: $55.00 through $95.00
$100.00 – $160.00Price range: $100.00 through $160.00
$35.00 – $50.00Price range: $35.00 through $50.00
$35.00 – $50.00Price range: $35.00 through $50.00
The Bottom Line
CJC-1295 with DAC and without DAC are both effective growth hormone secretagogues with different practical applications. The DAC version offers convenience with weekly dosing and sustained GH elevation. The without-DAC version provides more physiological pulsatile release but requires multiple daily injections.
Your choice depends on research goals, protocol design, and whether you’re combining with other peptides. Neither is inherently superior—they serve different purposes. Many researchers eventually try both to compare response in their specific experimental context.
For convenience and simplicity, the DAC version wins. For physiological mimicry and combination protocols, the without-DAC version is preferred. Both can produce meaningful results when used consistently within well-designed research frameworks.
Ready to explore growth hormone research? Check out our CJC-1295 and combination products to support your research protocols.
References
Disclaimer: All peptides and products mentioned are strictly for research purposes only and are not for human or animal use. This content is for informational purposes only and should not be considered medical advice. Always consult qualified professionals before starting any research protocol.
Related Posts
BPC-157 Peptide: Is Gut Healing With Angiogenesis Always Positive?
Curious about how BPC-157 peptide supports tendon-repair, gut recovery, and anti-inflammatory action? Dive in as we explore whether its unique gut healing boost through angiogenesis is always a positive—or if there’s more to the story than meets the eye.
Bacteriostatic Water: Why Use Bacteriostatic Water?
When it comes to the safe reconstitution of sensitive compounds, not all water is created equal. Discover the simple but powerful ingredient that makes this sterile solution a lab essential for keeping your materials pure and stable.